PharmaLundensis
Sweden - LundBiotechnology
Focus: PharmaLundensis is a Swedish biotech specialist in chelation therapeutics targeting heavy metal toxicity and neurological conditions. The company operates at early stage with a legacy portfolio of diagnostic radiopharmaceuticals and emerging pipeline programs.
Profile data last refreshed 9h ago · AI intelligence enriched 1w ago
Open Jobs
0
About PharmaLundensis
AI assessmentNot HiringNo open roles listed right now. Follow PharmaLundensis to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from PharmaLundensis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Declining
LOE Approaching
Legacy diagnostic radiopharmaceutical with imminent loss of exclusivity; no revenue concentration data disclosed.
Help build intelligence for PharmaLundensis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.